



## LOW-ENTITY UND BASKET TRIALS

Zur Unterstützung der Patientenrekrutierung finden Sie nachfolgend aktuell laufende **low-entity-** (geplante Fallzahl am Zentrum < 2 Patienten pro Jahr) sowie **Basket-** (multiple Tumorarten und/oder Altersgruppen (adult und pädiatrisch) **Therapiestudien** incl. der wichtigsten Einschlusskriterien. Nutzen Sie diese Informationen gerne, um potentielle Zuweiser zu informieren.

## LOW-ENTITY TRIALS

### DERMATOLOGISCHE ONKOLOGIE

#### **Malignes Melanom – IMA203-301**

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial To Evaluate Efficacy, Safety, And Tolerability Of IMA203 Versus Investigator's Choice In Patients With Previously Treated, Unresectable Or Metastatic Cutaneous Melanoma (ACTEngine(r) IMA203-301)  
Cohort specific either first- or later line | cohort specific with MSI-H/dMMR

[> zur Synopse](#)

#### **Malignes Melanom – IMC-F106C-301**

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial To Evaluate Efficacy, Safety, And Tolerability Of IMA203 Versus Investigator's Choice In Patients With Previously Treated, Unresectable Or Metastatic Cutaneous Melanoma (ACTEngine(r) IMA203-301)  
HLA-A\*02:01 positive | stadium IV or inoperable stadium III

[> zur Synopse](#)

### HÄMATOLOGISCHE NEOPLASMIEN

#### **Akute lymphatische Leukämie - AZ\_B-ALL\_SYRUS**

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

CD19 positive B-ALL | relapsed/refractory | Ph+ only if intolerant to TKIs

[> zur Synopse](#)

#### **Akute lymphatische Leukämie – GMALL-Isatuximab**

A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia

CD38 positive T-ALL | cohort 1: relapsed/refractory, cohort 2: MRD

[> zur Synopse](#)

## THORAXONKOLOGIE

### **Nicht kleinzelliges Lungenkarzinom - Beamion LUNG-2**

Beamion LUNG-2: A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

HER2 mutation | first-line | not eligible for curative therapy

[> zur Synopse](#)

### **Nicht kleinzelliges Lungenkarzinom - M041552**

Randomized, open label, multicenter, phase III Study of Entrectinib versus Crizotinib in patients with locally advanced or metastatic non-small cell lung cancer harboring ROS1 gene rearrangements with and without central nervous system metastases

No prior treatment with a ROS1 TKI

[> zur Synopse](#)

## PÄDIATRISCHE ONKOLOGIE

### **Akute myeloische Leukämie - ITCC-101/APAL2020D**

A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

ohne FLT3-ITD | bei Patienten, die nach 2. Relaps fit für weitere Chemotherapie oder nach 1. Relaps wenn nicht für Anthrazyklin-Behandlung geeignet

[> zur Synopse](#)

## BASKET TRIALS

### **ANV600-001**

A first-in-human, open-label Phase 1/2 study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors

Phase I: Advanced solid tumors; Phase II: unresectable / progressed Melanoma, second-line NSCLC, recurrent / unresectable HNSCC

[> zur Synopse](#)

### **CONCLUDE**

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360, a TOP1i ADC Targeting Claudin 18.2 (CLDN18.2) in Adult Participants with Advanced Solid Tumours

Claudin 18.2 pos | mind. Zweitlinie | Pankreaskarzinom, Karzinom des gastroösophagealen Übergangs, Magenkarzinom, Cholangioläres Karzinom

[> zur Synopse](#)

## Goblet

GOBLET (REO 029) A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment combinations with peLarEorep and aTezolizumab

All GI tumors



[> zur Synopse](#)

## PANTUMOR-1

Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours

Solid tumors | Her2 mut /amp / overexpression

[> zur Synopse](#)

## SIBYL

ObServation of Therapy Response With LIiquid BiopsY evaLuation

NSCLC, Colorectal Cancer, Breast Cancer | unresectable, advanced



[> zur Synopse](#)



= Studien aus kooperierenden Häusern im Rahmen des Hessischen Onkologiekonzepts, Versorgungsgebiet Frankfurt-Offenbach



Universitäres Centrum für Tumorerkrankungen (UCT)  
Clinical Trial Center Network (CTCN)  
[ctcn-zentrale@med.uni-frankfurt.de](mailto:ctcn-zentrale@med.uni-frankfurt.de)  
<https://www.uct-frankfurt.de/>

[Impressum](#) | [Datenschutz](#) | [Abbestellen](#)